Literature DB >> 18458279

Narrative review: buprenorphine for opioid-dependent patients in office practice.

Lynn E Sullivan1, David A Fiellin.   

Abstract

The profile of opioid dependence in the United States is changing. Abuse of prescription opioids is more common than that of illicit opioids: Recent data indicate that approximately 1.6 million persons abuse or are dependent on prescription opioids, whereas 323,000 abuse or are dependent on heroin. Despite this prevalence, nearly 80% of opioid-dependent persons remain untreated. One option for expanding treatment is the use of buprenorphine and the buprenorphine-naloxone combination. Buprenorphine is a partial opioid agonist that can be prescribed by trained physicians and dispensed at pharmacies. This article addresses the clinical presentation of a patient with opioid dependence and describes the relatively new practice of office-based treatment with buprenorphine-naloxone. The different components of treatment; the role of the physician who provides this treatment; and the logistics of treating this growing, multifaceted patient population are also examined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458279      PMCID: PMC3694223          DOI: 10.7326/0003-4819-148-9-200805060-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  68 in total

Review 1.  Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Authors:  John Mendelson; Reese T Jones
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

2.  Induction of patients with moderately severe methadone dependence onto buprenorphine.

Authors:  A Glasper; L J Reed; C J de Wet; M Gossop; J Bearn
Journal:  Addict Biol       Date:  2005-06       Impact factor: 4.280

3.  Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

Authors:  P J Fudala; E Yu; W Macfadden; C Boardman; C N Chiang
Journal:  Drug Alcohol Depend       Date:  1998-03-01       Impact factor: 4.492

4.  Buprenorphine and naloxone interactions in methadone maintenance patients.

Authors:  J Mendelson; R T Jones; S Welm; J Brown; S L Batki
Journal:  Biol Psychiatry       Date:  1997-06-01       Impact factor: 13.382

Review 5.  Rapid and ultrarapid opioid detoxification techniques.

Authors:  P G O'Connor; T R Kosten
Journal:  JAMA       Date:  1998-01-21       Impact factor: 56.272

Review 6.  Use of buprenorphine in pregnancy: patient management and effects on the neonate.

Authors:  Rolley E Johnson; Hendrée E Jones; Gabriele Fischer
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

Review 7.  Clinical pharmacology of narcotic antagonists.

Authors:  C P O'Brien; R Greenstein; J Ternes; G E Woody
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

8.  Buprenorphine and naloxone interactions in opiate-dependent volunteers.

Authors:  J Mendelson; R T Jones; I Fernandez; S Welm; A K Melby; M J Baggott
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

Review 9.  The effects of adulterants and selected ingested compounds on drugs-of-abuse testing in urine.

Authors:  Amitava Dasgupta
Journal:  Am J Clin Pathol       Date:  2007-09       Impact factor: 2.493

10.  Effects of buprenorphine and methadone in methadone-maintained subjects.

Authors:  S L Walsh; H L June; K J Schuh; K L Preston; G E Bigelow; M L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

View more
  22 in total

1.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink
Journal:  CMAJ       Date:  2009-12-07       Impact factor: 8.262

2.  Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians.

Authors:  E Jennifer Edelman; An T Dinh; Brent A Moore; Richard S Schottenfeld; David A Fiellin; Lynn E Sullivan
Journal:  J Addict Med       Date:  2012-06       Impact factor: 3.702

3.  A scalable, automated warm handoff from the emergency department to community sites offering continued medication for opioid use disorder: Lessons learned from the EMBED trial stakeholders.

Authors:  Osama M Ahmed; Jodi A Mao; Stephen R Holt; Kathryn Hawk; Gail D'Onofrio; Shara Martel; Edward R Melnick
Journal:  J Subst Abuse Treat       Date:  2019-05-07

4.  Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.

Authors:  Sharon Stancliff; Herman Joseph; Chunki Fong; Terry Furst; Sandra D Comer; Perrine Roux
Journal:  J Addict Dis       Date:  2012

Review 5.  Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.

Authors:  Jean Bonhomme; Ruth S Shim; Richard Gooden; Dawn Tyus; George Rust
Journal:  J Natl Med Assoc       Date:  2012 Jul-Aug       Impact factor: 1.798

6.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

7.  Illicit drug use among women with children in the United States: 2002-2003.

Authors:  Leigh Ann Simmons; Jennifer R Havens; Jason B Whiting; Jennifer L Holz; Henrietta Bada
Journal:  Ann Epidemiol       Date:  2009-03       Impact factor: 3.797

8.  Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.

Authors:  Gregory M Lucas; Alicia Young; Deborah Donnell; Paul Richardson; Apinun Aramrattana; Yiming Shao; Yuhua Ruan; Wei Liu; Liping Fu; Jun Ma; David D Celentano; David Metzger; J Brooks Jackson; David Burns
Journal:  Drug Alcohol Depend       Date:  2014-06-19       Impact factor: 4.492

9.  The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.

Authors:  E Jennifer Edelman; Tongtan Chantarat; Sarah Caffrey; Amina Chaudhry; Patrick G O'Connor; Linda Weiss; David A Fiellin; Lynn E Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-03-15       Impact factor: 4.492

Review 10.  Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist.

Authors:  Kinna Thakarar; Zoe M Weinstein; Alexander Y Walley
Journal:  Postgrad Med J       Date:  2016-03-22       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.